Agios Pharmaceuticals, Inc. (AGIO)
Nasdaq · Healthcare · Biotechnology
$31.25−1.73%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.9B
- 52-week range
- $22.24 – $46.00
- 52-week change
- −22.19%
- EPS (trailing)
- −$7.01
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $54.0M (+48.03%)
- Net income
- −$413M
- Operating margin
- −873.9%
- Diluted EPS
- −$7.12
- Free cash flow
- −$377M
From the company’s annual report on SEC EDGAR.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 539 employees · agios.com